Purpose of review Significant achievements have been obtained in cancer treatment, but the clinical relevance of drug approach in daily practice remains questionable due to the high costs, limited efficacy, and negligible influence on quality of life. A new concept is emerging which is based on the early combination of chemotherapy and nutrition therapy.
INTRODUCTION
During the past decade, better understanding of the mechanisms of carcinogenesis, cancer progression and resistance to treatment has been achieved. Therefore, it is not surprising that the incidence rates of many cancers and the relative risk of cancer death are both declining [1] . Nevertheless, the current drug approach to cancer is disappointing since it delivers statistically significant results, whose clinical relevance is questionable due to high costs, suboptimal response rate, increased toxicity and negligible impact on quality of life [2 && ,3]. It is therefore becoming imperative to integrate traditional therapies with new concepts, which may enhance their efficacy, ideally at a fraction of the financial costs currently needed.
A promising concept is combination of drugs targeting cancer cells with strategies supporting the host or priming his/her metabolism. Indeed, in daily clinical practice cancer cells do not exist per se, rather patients with cancer. Therefore, any effective therapeutic strategy should target the cancer while simultaneously supporting the host [4] . Preliminary observations showed that integrating supportive care, that is, psychological support, nutritional care and pain control, during active treatment in lung cancer patients resulted in reduced distress and enhanced survival [5] . It is therefore tempting to speculate that specific nutrients given at specific doses and at critical time points in the clinical journey of cancer patients may increase response rate to treatment and improve patient centred outcomes.
by clinicians and epidemiologists since the late 1980s. Omega-3 fatty acids are mainly derived from fish oil, and are characterized by the presence of a double bond on the third carbon atom from the methyl end of the carbon chain (omega end). The omega-3 fatty acids with clinically relevant effects in the oncology setting are eicosapentaenoic acid (EPA), docosahexaenoic acid (DHA) and a-linolenic acid (ALA), due to their anti-inflammatory effects.
Omega-3 fatty acids, and in particular EPA, are metabolized by the same enzymes, that is, lipoxygenase and cyclooxygenase, which metabolize polyunsaturated omega-6 fatty acids, including arachidonic acid. However, the mediators of inflammation, that is, thromboxanes and prostaglandins, deriving from arachidonic acid, exert greater inflammatory activity when compared with the mediators deriving from EPA. Therefore, a diet rich in EPA would negatively modulate the inflammatory cascade [6 && ]. Considering the impact of inflammation on the initiation and progression of cancer cells [7], a diet rich in omega-3 fatty acids may protect from cancer, at least at certain sites [8 & ]. Gerber [9 & ] has recently reviewed prospective and case-control observational studies investigating the possible protective effects of the dietary intake of omega-3 fatty acids on cancer development. Available evidence seems to suggest that ALA per se is neither a risk factor nor a beneficial factor for cancers. Interestingly, only observational studies on colorectal, prostate and breast cancers showed limited evidence on the possible role of omega-3 fatty acids in cancer prevention because insufficient homogeneity of the observations [9 & ]. Indeed, epidemiological studies suffer from heterogeneity due to inherent difficulties (i.e. confounding and dietary pattern context, measurement error, level of intake, genetic polymorphisms); nevertheless it appears that cancer prevention cannot be attributed to a single nutrient, but other factors, including genetic background and lifestyle, play an important role as well. This may explain why intervention studies involving single nutrients frequently failed to prevent chronic diseases [10].
OMEGA-3 FATTY ACIDS AND CANCER CACHEXIA
Progressive and irreversible deterioration of nutritional status, that is, cachexia, is a frequent complication of tumour growth. Unlike starvation-induced malnutrition, cancer cachexia is not reversed by standard nutritional support since cachexia results from the combination of anorexia, reduced food intake and profound metabolic changes which are responsible for the onset of anabolic resistance 
KEY POINTS
The clinical relevance of the current drug approach to cancer patients is at least questionable.
Early integration of supportive care into active treatment increases survival and reduces psychological distress of cancer patients.
Omega-3 fatty acids are metabolically active lipids with anti-inflammatory properties.
Omega-3 fatty acids may reverse cancer cachexia, improve muscle mass and lean body mass, and promote weight maintenance.
Considering the role of inflammation in tumour metabolism and in drug resistance, there is a strong rationale for their use in combination with anticancer therapies.
Although limited evidence exists regarding the role of omega-3 fatty acids in preventing tumour development, their use in cancer patients has been demonstrated in small studies to improve nutritional status and function, to possibly reduce cancer treatment toxicity and increase response rate. ]. Available data are insufficient to draw any robust recommendation for the use of omega-3 fatty in the prevention/treatment of cancer cachexia since available clinical studies are highly heterogeneous (Table 1) . Also, the number of cancer patients involved in these trials is generally limited, making it difficult to generalize the results obtained to the whole oncologic population. Therefore, the many confounding elements still permeating this research field may contribute to the lack of robust evidence. Indeed, when well designed although small clinical trials are considered (i.e. homogeneous patients not yet in the refractory phase of cachexia, stratified in active and control groups, supplemented with enough dose of omega-3 fatty acids on top of energy and protein requirements), then the results appear promising orally supplemented 31 head and neck cancer patients for 5 days before each cycle of chemotherapy with an enriched formula, containing 3 g EPAþDHA/day, immune enhancing amino acids and a mix of antioxidant vitamins and micronutrients. At baseline, levels of inflammatory, proangiogenic and pro-oxidative stress markers were increased, but inflammatory markers significantly decreased after supplementation [26] . After 6 weeks of radiochemotherapy, 19 of the 31 eligible patients experienced at least an NCI grade 3 or 4 acute toxicity, including five patients (16%) with grade 3 or 4 mucositis. The clinical relevance of this study is limited by the lack of a control group. However, the authors highlight that in their study the incidence of severe acute mucositis was 16 vs. 45% in the available and comparable literature [26] .
Although published studies are inconclusive due to the small populations involved and the lack of control groups, nevertheless the robustness of observational studies seems to suggest a causative inverse link between muscle mass and cancer treatment toxicity. Therefore, the role of muscle mass in preventing chemotherapy-induced toxicity should be further investigated, and factors associated to muscle mass, that is, physical exercise or drug pharmacokinetics, should also be considered.
Neutropenia and impaired neutrophil function are frequent toxic effects of cancer chemotherapy and lead to dose reduction when severe. Bonatto et al. [27 & ] recently tested whether omega-3 fatty acids supplementation improved neutrophil function in cancer patients receiving chemotherapy. Results show that nonsupplemented cancer patients receiving 5-fluorouracil and leucoverin lost 2.5 kg of weight over the 8 weeks of the study. Also, the number of blood polymorphonuclear cells, mainly neutrophils, and their functions (phagocytosis and hydrogen peroxide production) significantly decreased. In contrast, daily supplementation of 0.3 g EPA and 0.4 g DHA prevented these decreases and actually increased body weight, polymorphonuclear cell number, phagocytosis and superoxide production. These results are encouraging but more trials are needed to assess whether the protective effects of EPA and DHA on neutrophil number and function translate into clinically relevant outcomes (i.e. prevention of infections, reduction of treatment interruptions due to neutropenia).
OMEGA-3 FATTY ACIDS AND RESPONSE TO TREATMENT
The tumour inflammatory microenvironment plays a major role in growth, invasiveness and resistance to therapy [28] . On the contrary, food is a potent inducer of metabolic responses. Therefore, modulation of food intake may impact on tumour growth, by sensitizing cancer cells to chemotherapy and increasing resistance of normal cells to the toxic effects. In animal models, this hypothesis has been tested by using extreme nutritional stress. Lee et al. [29 && ] studied the effects of short term fasting on cultured cancer cells and in animal models. Results obtained showed that multiple cycles of fasting promote differential stress sensitization in a wide range of tumours and could potentially replace or augment the efficacy of certain chemotherapy drugs in the treatment of various cancers [29 && ]. However, translation of this approach in clinical practice could be difficult and not advisable since cancer patients are already prone to the development of malnutrition and cycles of fasting may accelerate the onset of cachexia [30 & ]. Since tumour growth appears to be related to the circulating levels of glucose and insulin-like growth factor I (IGF-I) [29 && ], any nutritional intervention inhibiting the IGF-I axis may also lead to increased sensitization of cancer cells to chemotherapy and increased resistance of normal cells to cancer treatment toxicity. Interestingly, experimental evidence showed that plasma IGF-I decreased with increasing dietary omega-3 : omega-6 ratio [31] . Therefore, omega-3 fatty acid supplementation could represent a clinically relevant adjuvant therapy in cancer patients.
Recent evidence shows that omega-3 fatty acid supplementation increases cancer cell apoptosis. Benais-Pont et al. [32] demonstrated that preincubation with omega-3 fatty acids induced a dosedependent additive decrease in colorectal cancer cell survival after irradiation. Evaluation of the underlying mechanisms indicated that omega-3 fatty acids mainly decreased the cell number via apoptosis induction [32] . Supporting this evidence, Fukui et al. [33] demonstrated that feeding animals with a diet supplemented with high levels of EPA and DHA inhibits the growth of human pancreatic cancer xenografts in athymic nude mice by inducing oxidative stress and cell death. However, EPA can concomitantly induce autophagy in cancer cells, and the induction of autophagy diminishes its ability to induce apoptotic cell death [33] .
In cancer patients, promising results have been obtained. Bougnoux et al. [34] evaluated the safety and efficacy of the addition of 1.8 g DHA daily to an anthracycline-based chemotherapy regimen in 25 breast cancer patients with rapidly progressing visceral metastases. Results obtained showed that the objective response rate, time to progression and overall survival were within the ranges reported in the literature [34] . However, when patients are stratified according to high or low DHA incorporation into cell membranes, survival is almost doubled in high incorporating vs. low incorporating patients (34 and 18 months, respectively) and longer than the average overall survival reported in the literature, that is, 18-23 months [34] . It is likely that tumour cells were made more sensitive to chemotherapy when membrane lipids were enriched with DHA, an oxidative stress-inducing lipid [34] . More recently, Murphy et al. [25 && ] studied 46 lung cancer patients receiving first-line chemotherapy. Patients were invited to take fish oil (2.5 g EPA þ DHA/day) during chemotherapy cycles, as tablets or liquid product. At the end of the study, patients supplemented with fish oil (n ¼ 15) had an increased response rate (60.0 vs. 25.8%) and greater clinical benefit (80.0 vs. 41.9%) when compared to those observed in the standard of care group. Surprisingly, the incidence of dose-limiting toxicity did not differ between groups although fish oil supplemented patients increased their muscle mass [20 & ,25 && ]. Also, 1-year survival tended to be greater in the fish oil group (60.0 vs. 38.7%; P ¼ 0.15) [25 && ]. When considered together, this evidence suggests that omega-3 fatty acids may exert a direct inhibitory effect on cancer cells in vivo (proapoptotic effect?), beyond their potential for reducing cancer treatment toxicity. Considering the cost of omega-3 fatty acid supplementation when compared to chemotherapy, even achieving a 30% increase in response rate by integrating EPA/DHA in standard treatment of cancer patients would prove to be highly cost-effective.
CONCLUSION
Integration of omega-3 fatty acid supplementation into the therapeutic approach to cancer patients is a novel and promising concept, which goes beyond their potential role in reversing cancer cachexia, promoting weight maintenance and improving muscle mass. Preliminary observations suggest that statistically significant and clinically relevant achievements could be obtained in terms of enhanced efficacy of anticancer drugs, reduced toxicity and enhanced quality of life. The next frontier is including nutrition therapy into clinical trials testing the efficacy of chemical entities in cancer patients: in this way, by testing this combination in a large population, a definitive answer to the therapeutic role of omega-3 fatty acids will be achieved and general recommendations could be issued. Evidence in this area is being constantly produced, which strongly suggests the general tenet of clinical nutrition, that is, 'never underestimate the power of food'. This opinion paper authored by eminent oncologists recognizes that cancer treatment toxicity is an under-recognized clinical problem. However, the authors fail to recognize that maintenance/restoration of muscle mass is a promising therapeutic strategy to limit cancer treatment toxicity. 
